Marksans Pharma has scheduled its earnings conference call for the first quarter of fiscal year 2027 on Thursday, August 13, 2026, at 4:30 PM IST. The management team will present and discuss the company's unaudited financial results for the quarter ended June 30, 2026, covering both standalone and consolidated performance metrics. This disclosure was made pursuant to Regulation 30 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, with notifications submitted to BSE Limited and the National Stock Exchange of India Limited on August 03, 2026.

Conference Call Leadership

Founder, Chairman and Managing Director Mark Saldanha and Chief Financial Officer Jitendra Sharma are scheduled to lead the discussion. DAM Capital Advisors Ltd will manage the proceedings, with Nitin Agarwal serving as the analyst lead. For further assistance regarding the call logistics, DAM Capital Advisors Limited can be contacted at +91 22 4202 2568 / 2638 or via email at nitin.a@damcapital.in and payal@damcapital.in .

Dial-in Access Details

Participants can access the call via universal dial-in numbers +91 22 6280 1384 or +91 22 7115 8285. Investors are advised to dial in five to ten minutes prior to the scheduled start time to ensure connectivity. A diamond passcode link is also available for access. International participants may use the toll-free numbers provided for specific regions, as detailed below:

Post-Call Resources

Following the conference call, Marksans Pharma will host the presentation, audio recording, and transcript on its official website. These materials will be available at https://www.marksanspharma.com/earnings-call-transcripts.html for public access. The notice was signed by Harshavardhan Panigrahi, Company Secretary.

Marksans Pharma Ltd has completed the acquisition of 100% share capital of Germany-based ABCNow GmbH. The company finalized the transaction on July 20, 2026, expanding its international footprint through this strategic move.

The acquisition was disclosed to the stock exchanges under Regulation 30 read with Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulatory filing confirms that the process to acquire the entire share capital of the German entity has been concluded.

Acquisition Details

The following table summarises the key details of the completed transaction:

The completion of this acquisition marks a significant development for Marksans Pharma as it integrates the new subsidiary into its operations. The company had initially intimated the exchanges about the proposed acquisition on July 8, 2026.